BioSpace News Archive

Pharm Country

Aquavit Files Additional IND for DTX-024, a New Botulinum Toxin With Microchannel Technology™ for Palmar Hyperhidrosis

Aquavit Holdings has submitted to FDA an IND for its DTX-024, for the treatment of palmar hyperhidrosis using its patented microchannel technology™.

March 18, 2023
·
3 min read
Policy

Public Advisory - Two lots of cystic fibrosis drug Cayston recalled due to the potential of cracked glass vials

Health Canada is advising the public that Gilead Sciences Incorporated recalled two lots of the cystic fibrosis drug Cayston on March 1, 2023, due to the potential of cracked glass vials in those lots, which may introduce glass particles into the medication.

March 18, 2023
·
2 min read
Drug Development

Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks

UCB, a global biopharmaceutical company, announced detailed positive results from two Phase 3 studies evaluating the efficacy and safety of bimekizumab in the treatment of adults with moderate to severe hidradenitis suppurativa.

March 18, 2023
·
14 min read
Drug Development

Late-Breaking Phase 3 Data at AAD 2023 Show Oral Investigational Medicine Deuruxolitinib Significantly Improved Scalp Hair Regrowth in Alopecia Areata

Concert Pharmaceuticals, a company recently acquired by Sun Pharmaceutical Industries Limited, announced the presentation of data from its Phase 3 clinical trial, THRIVE-AA2.

March 18, 2023
·
8 min read
Biotech Beach

Connect Biopharma CBP-201 Atopic Dermatitis China Pivotal Study Showed Rapid Relief of Patient Symptoms

Connect Biopharma Holdings Limited announced that data from Stage 1 of the ongoing pivotal CBP-201 China trial in moderate-to-severe atopic dermatitis showed rapid relief from symptoms, as early as week one in some cases, and no efficacy plateau at Week 16.

March 18, 2023
·
5 min read
Drug Development

Incyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo

Incyte announced new data from a Phase 2b clinical trial evaluating the safety and efficacy of povorcitinib, an investigational oral JAK1 inhibitor, in adult patients with extensive nonsegmental vitiligo.

March 18, 2023
·
9 min read
BioCapital

California Selects Civica Rx as Its Insulin Manufacturing Partner

Civica Inc. announced it will manufacture insulins for the State of California’s CalRx Biosimilar Insulin Initiative as part of its insulin manufacturing work.

March 18, 2023
·
5 min read